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which significantly reduces the incidence of break- 
through IFI, may more be effective than treatment 
of established IFIs. 
Patients with IFIs POS (n = 16) FLU (n = 27) 
Total deaths, n (%) 10 (63) 18 (67) 
Cause of death, n (%) 
Progression of IFI 2 (13) 6 (22) 
HSCT/GVHD 2 (13) 6 (22) 
Adverse events 6 a (38) 5 b (19) 
Unknown 0 1 (4) 
alnc[udes: intracrania[ hemorrhage, brain stem herniation, bac- 
teria[ sepsis, cardiopu[monary arrest, disseminated varicella 
zoster, upper ~astrointestina[ b[eed. 
blnc[udes: diffuse a[veo[ar hemorrhage, cardiac and respiratory 
fai[ure, cytornesalovirus pneumonia, respiratory insufficiency. 
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Background: Risk factors for adenovirus (ADV) in- 
fection following a[[ogeneic stem ceil transplan- 
tation (ASCT) from retrospective studies include 
graft versus host disease (GVHD), T-ceil depleted 
grafts, [ymphopenia, retransp[antation, total body 
irradiation, use of multiple immunosuppressives, 
and mismatched or unrelated donors. 
Objectives: To perform a case-control study to 
ascertain risk factors for ADV infection in pediatric 
ASCT patients (pts). 
Methods: We prospectively studied 40 children 
from 9/8/03 to 12/1/05 for ADV infection for up 
to 1 year (y) following ASCT. The week prior to 
ASCT, a throat swab, urine, and stool were sent for 
viral culture, and plasma was sent for ADV PCR. The 
same specimens were obtained weekly for the first 
100 days (d), then monthly until 1 y after ASCT. We 
defined ADV infection as: (1) a positive ADV PCR, 
(2) >2 positive ADV cultures from separate sites, or 
(3) 1 positive culture plus clinical evidence of ADV. 
1 ADV infected pt was matched with 2 non-infected 
pts for gender and survival to at [east 21 d after the 
index case developed ADV. Risk factors were then 
compared. 
Results: 6 (15%) of the 40 ASCT pts developed 
ADV infection. Median age of case pts was 1.4y, 
while that of control pts was 9.3y. 2 of 6 
case pts received anti-thymocyte globulin (ATG) 
post-transplant as opposed to 0 of 2 matched 
controls. 2 of 6 case pts underwent previous ASCT 
compared with 1 of 12 controls. Case pts recovered 
their lymphocyte counts to 200/ram 3 a median of 
18.5 d following transplant while control pts were 
14 d. Matched related transplants occurred in only 
1 of 6 case pts but in 6 of 12 control pts. There 
were no differences between case and control pts 
regarding ethnicity, diagnosis leading to transplant, 
pretreatment conditioning, episodes of GVHD, or 
treatment with gancic[ovir. 
Conclusions: Younger age, receipt of ATG post- 
transplant, and a longer time to lymphocyte re- 
covery appeared to be risk factors for developing 
ADV infection. GVHD, total body irradiation, and 
conditioning regimen were not. Receipt of a trans- 
plant from a completely matched related donor 
appeared protective. 
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Background: CMV remains an important factor for 
outcome of a[[ogeneic stem ceil transplantation 
(SCT). The serological status of both donors and 
recipients are important factors for transplant out- 
come. 
Objective: Our aim was use the registry of the Eu- 
ropean Group for Blood and Marrow Transplantation 
to study trends over time as we[[ as analyzing the 
effects of age, gender, and country on the donor 
and recipient CMV serostatus. 
Patients ~ Methods: 40,311 patients and 23,048 
donors were selected from the registry database. 
The patients were transplanted 1985-2004. Logis- 
tic regression models were constructed predicting 
seropositivity using as covariates year of SCT, age, 
gender, and country for both patients and donors 
separately. 
Results: Females had a higher likelihood to be 
seropositive than males both among patients 
(OR 1.22; 1.15-1.30; p<.001) and donors (OR 1.23; 
1.13-1.34; p<0.001). The risk to be seroposi- 
tive increased by age (patients OR 1.19/decade; 
1.17-1.21; p<0.001; donors OR 1.24/decade; 
1.22-1.27; p<0.001) but decreased by calendar 
year (patients OR 0.98/year, 0.97-0.99; p < 0.001; 
donors 0.98/year; 0.97-0.98; p=0.001). There 
were major differences between different coun- 
tries with the BENELUX countries having the lowest 
and Italy the highest probabilities to be seroposi- 
tive for both patients and donors. 
